Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase like 3 conjugates promotes bladder cancer development

Xiaoling Ying1,2, Xu Jiang1, Haiqing Zhang1, Bixia Liu1, Yapeng Huang3, Xiaowei Zhu3, Defeng Qi3, Gang Yuan4, Junhang Luo2 and Weidong Ji1*

Abstract
Accumulating evidence has revealed significant roles for N6-methyladenosine (m6A) modification in the development of various cancers. We previously demonstrated an oncogenic role of m6A-modified CUB domain containing protein 1 (CDCP1) in bladder cancer (BC) progression. However, the biological functions and underlying molecular mechanisms of engineered programmable m6A modification of CDCP1 mRNA in BC remain obscure. Here, we established a targeted m6A RNA methylation system by fusing the catalytic domain of methyltransferase like 3 (METTL3CD) to RCas9 as the RNA-targeting module. The constructed RCas9- METTL3 retained methylation activity and mediated efficient site-specific m6A installation in the presence of a cognate single guide RNA and short protospacer adjacent motif-containing ssDNA molecule. Subsequently, targeting m6A installation onto the 3’ untranslated region of CDCP1 promoted CDCP1 mRNA translation and facilitated BC development in vitro and in vivo. Our findings demonstrate that the RCas9-METTL3 system mediates efficient site-specific m6A installation on CDCP1 mRNA and promotes BC development. Thus, the RCas9-METTL3 system provides a new tool for studying m6A function and a potential strategy for BC epitranscriptome-modulating therapies.

Background
RNA epitranscriptomics has gained popularity in recent years [1]. To date, more than 160 different RNA modifications have been identified [2]. Of these, N6-methyladenosine (m6A) is the most prevalent RNA modification in eukaryotes [3]. m6A modification is especially relevant to the occurrence and development of tumors. m6A methyltransferases may play oncogenic or suppressive roles in malignant tumors. Methyltransferase like 3 (METTL3) promotes the progression of bladder cancer (BC) by regulating the expression levels of AFF4, IKBKB, RELA, MYC, ITGA6, and CUB domain-containing protein 1 (CDCP1) or by accelerating pre-miR221/222 maturation in an m6A-dependent manner [4–7]. However, METTL14 inhibits the self-renewal capacity of BC-initiating cells and bladder tumorigenesis by modulating Notch1 m6A levels [8]. The methyltransferase family proteins recognize their specific sites and modify targeted transcripts differentially, suggesting that the location of the m6A modifications on mRNA transcripts may underlie the observed differences. As knockdown or overexpression of m6A methyltransferases leads to altered m6A content at numerous sites on many transcripts, it is difficult to determine the roles of specific m6A sites and reveal the causal relationships between individual m6A modifications and biological function.

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Therefore, generating an efficient, manipulative, and targeted site-specific m^6^A installation system will provide a critical tool for better understanding the role of locus-specific m^6^A modification in multiple biological processes.

Recent studies have repurposed CRISPR/Cas9 for RNA targeting (RCas9) by providing protospacer adjacent motif (PAM) as part of an oligonucleotide (PAM-mer) that hybridizes to the target RNA. In our previous study, we reported an oncogenic role of m^6^A-modified CDCP1 in BC progression. We hypothesized that the fusion of m^6^A regulators to RCas9 should manipulate m^6^A modification of CDCP1 for exploring the biological function of locus-specific m^6^A RNA methylation.

In this study, we linked the METTL3 catalytic domain (METTL3CD) to the N-terminus of dCas9, fused two SV40 nuclear localization signal (NLS) sequences at the C terminus, and established a targeted RNA methylation system that enables site-directed m^6^A incorporation in target transcripts by targeting single guide (sg) RNAs.
and short PAM-containing ssDNA molecules (PAMmers) against CDCP1. We demonstrate that targeting m6A installation onto the 3′ untranslated region (UTR) of CDCP1 enhances CDCP1 mRNA translation and facilitates BC development in vitro and in vivo.

Results and discussions

The RCas9-METTL3 system enhances m6A modification

To establish a targeted RNA methylation system, we fused the METTL3CD to the N-terminus of nuclease-null Cas9 (dCas9) tagged with an enhanced green fluorescent protein (EGFP; Fig. 1a). Then, dCas9 was fused to two SV40 NLS sequences at the C terminus. Primer sequences for polymerase chain reaction (PCR) amplification are summarized in Table S1. Next, we sought to test specific m6A levels in human cells. We designed guide RNAs targeting the 3′ UTR of CDCP1 or epidermal growth factor receptor (EGFR) mRNAs. We designed a λ2 sgRNA-PAMmer pair as a negative control (sgRNA and PAMmer sequences are listed in Table S2). The methylated RNA immunoprecipitation (MeRIP) assays and real-time quantitative PCR (RT-qPCR; the primers used are listed in Table S4) of CDCP1 revealed six- to seven-fold higher methylation from CDCP1-targeted dCas9–M3 but none from dCas9 without methyltransferase constructs (Fig. 1b). We observed a smaller increase (1.8-fold) in m6A modification from dCas9–M3 containing an NLS tagged with EGFP and CDCP1 sites for what similar sequences.

In agreement with the CDCP1 results, RCas9-M3 increased m6A levels of EGFR (60.5-, 32.7-, and 24.6-fold, respectively) only when fused to dCas9-M3 and supplied with EGFR-targeting guide RNA-PAMmers (Fig. S1). To further confirm the effect of METTL3CD-RCas9 on targeting site-specific m6A modifications, we designed probe L and probe R against the CDCP1 3′ UTR at three m6A sites (155, 173, and 212; numbered relative to the first nucleotide of the 3′ UTR) (Table S3) [7] and used the T3 ligase to concatenate the two probes onto templates that could be amplified by PCR. Thus, the amount of PCR products could be used to assess ligation efficiency and indicate the methylation status of each site (Fig. 1c). In transfected SV-HUC-1 cells, sgRNAs (155, 173, and 212) increased methylation at the #155, #173, and #212 sites, respectively (Fig. 1d), indicating that our constructed RCas9-M3 system can mediate efficient site-specific m6A modification. Our system-established stable cell lines via lentiviral transduction, providing an ideal tool for dissecting the biological function of locus-specific m6A RNA methylation.

Next, we assessed if RCas9-M3 could recognize specific mRNA substrates in human cells by testing whether dCas9-M3 containing an NLS tagged with EGFP and mRNA was co-exported from the nucleus in the presence of a cognate sgRNA and PAMmer designed to recognize the mRNA. We transfected dCas9-M3 into SV-HUC-1 cells and observed that 87% of cells showed an EGFP signal in the nucleus. When the cells were co-transfected with CDCP1-targeting sgRNA plasmid and PAMmer, only 18% of cells showed an EGFP signal in the nucleus (Fig. 1e and f). These observations suggest that dCas9-M3 is exported from the nucleus in the presence of a cognate sgRNA and PAMmer, consistent with a previous finding that RCas9 is exported from the nucleus in the presence of sgRNA targeting glyceraldehyde 3-phosphate dehydrogenase mRNA [9]. To further confirm that RCas9-M3 was exported from the nucleus by binding to target mRNA, RIP experiments were performed. Western blot analysis revealed that the EGFP or EGFP fusion proteins were of the expected size (Fig. 1h and Fig. S2a), RT-qPCR revealed that the relative abundance of CDCP1 or EGFR in targeting groups was significantly higher than that in non-targeting groups (Fig. 1g and Fig. S2b), indicating that the RCas9-M3 system binds to targeted mRNAs and mediates efficient site-specific m6A installation.

To evaluate the off-target effects of the RCas9-M3 system, we first predicted off-target gRNA binding sites for CDCP1 gRNAs by BLASTN using “somewhat similar sequences.” We chose the top three matching genes for sgRNA1/2 of CDCP1 (Fig. S3a). The methylation level of these off-target sites was detected by MeRIP-qPCR after transfection with dCas9-M3 and CDCP1 targeting sgRNAs or a non-targeting λ2 sgRNA. The results showed no significant effect on the methylation levels of these off-target loci (Fig.S3b), although two of them (SPEC1L, OR4A5) had slightly increased methylation, indicating that the off-target effect on tested transcripts was limited. Furthermore, we performed differential RNA-seq analysis to examine the effect of RCas9-M3 on the transcriptome. The results showed that a comparison of these constructs with non-targeting λ2 sgRNA control revealed more (> 1400 out of > 14,730 total genes analyzed) differentially expressed genes (false discovery rate (FDR) corrected P < 0.05 and more than twofold change; see Fig. S3c). Those changes in transcription may be caused by target methylation from RCas9-M3 upregulating CDCP1 protein levels. However, there were only a few (< 240 of > 14,730 total genes analyzed) differentially expressed genes between the CDCP1-sgRNA155–173 and CDCP1-sgRNA212 groups (Fig. S3d). These differences may be due to different m6A methylation levels in the two sgRNA groups. These findings suggest that RCas9-M3 exhibits satisfactory on-target efficiency.
**Fig. 2** Targeting of the CDCP1 m6A by RCas9-M3 facilitates bladder cancer (BC) development.

- **a-c** Targeted methylation by the RCas9-M3 system facilitates cancer progression in vitro. 
  - **a** MTT assay of cellular proliferation in SV-HUC-1 and METTL3-depleted T24 cells expressing the RCas9-M3 system.
  - **b** RCas9-M3 targeting of CDCP1 mRNA promotes cell migration. Scale bars: 100 μm; 200x.
  - **c** RCas9-M3 targeting of CDCP1 mRNA promotes cell invasion. Scale bars: 100 μm; 200x.

- **d-f** Targeted methylation by the RCas9-M3 system facilitates cancer progression in vivo. 
  - **d** Representative tumor images, **e** weights, and **f** growth curves are shown (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Ying et al. *Molecular Cancer* (2020) 19:169
Targeted methylation using RCas9-METTL3 promotes translation

We previously showed that m6A promotes the translation of CDCP1 mRNA and promotes bladder tumor growth [7]. m6A promotes lung cancer cell growth, survival, and invasion by enhancing EGFR mRNA translation [10]. To investigate whether RCas9-M3 facilitates the translation of targeted mRNAs, we performed a dual-luciferase reporter assay in 293 T using dual-luciferase vectors (psiCHECK-2) with a segment of the CDCP1 3’ UTR containing m6A sites or mutation of the three motifs (Fig. S4a). The results showed that the RCas9-M3 system significantly increased wild-type luciferase activity but not m6A motif-mutated luciferase activity compared to non-target control (Fig. S4b). We confirmed these results in stable SV-HUC-1 cells containing RCas9-M3. The wild-type or mutant-type psiCHECK-2-CDCP1-3’ UTR was transfected into the stable cells, and the relative fluorescence signal was measured. The results revealed that the wild-type but not mutant-type luciferase activity in the target group was significantly higher than that in the non-target groups (Fig. S4c). Even with a non-targeting PAMmer, cells containing dCas9-M3 using target sgRNA had higher luciferase activity than cells with non-target sgRNA. Luciferase activity was enhanced by the target PAMmer (Fig. S4b and S4c), suggesting that the sgRNA is the primary determinant of RNA substrate recognition. These results are consistent with the previous programmable RNA tracking in live cells showing that RNA binding by Cas9: sgRNA is independent of, but strengthened by, PAMmer [9]. Furthermore, CDCP1-sgRNA2 showed higher luciferase activity than CDCP1-sgRNA1 in stable SV-HUC-1 cells (Fig. S4c), suggesting that CDCP1-sgRNA2 has a higher translation effect. Next, we evaluated protein expression from the target genes using western blot analysis. CDCP1 or EGFR protein levels were significantly elevated in stably transduced SV-HUC-1 or METTL3-depleted HeLa cells compared to control cells (Fig. S4e and S4f). However, there was no significant difference in mRNA expression among each group (Fig. S4e and S4f). An immunofluorescence assay was performed to further confirm the western blot results (Fig. S4h). These results suggest that the RCas9-M3 targeted modification system can upregulate the translation of target genes.

Targeting of the CDCP1 m6A by RCas9-M3 facilitates BC development

To ascertain the function of the RCas9-M3 system in BC development, RCas9-M3 or control plasmids were stably transfected into SV-HUC-1 or METTL3-depleted HeLa cells. The MTT assay results showed that the cell proliferation rate in the RCas9-M3 targeting group was significantly higher than that in the non-targeting control group (Fig. 2a). Cell migration and invasion were enhanced in RCas9-M3 targeting cells compared to control cells (Fig. 2b and c). Furthermore, the CDCP1-sgRNA2 targeting group in METTL3-depleted T24 cells had higher viability and migration than the CDCP1-sgRNA1 targeting group and the non-targeting groups (Fig. 2a and b). Moreover, CDCP1-sgRNA2 showed higher luciferase activity than CDCP1-sgRNA1 in stable SV-HUC-1 cells (Fig. S4c). To further determine whether RCas9-M3 also facilitates BC development in vivo, METTL3-depleted T24 cells were stably transfected with dCas9, dCas9-M3, CDCP1-sgRNA2, CDCP1-PAMmer2, or λ2 sgRNA-PAMmer, and the transfected cells were injected into nude mice (5 x 10⁶ cells per mouse). After 4 weeks, the tumors were dissected from the mice and weighed (Fig. 2d and e). The tumor growth curves were drawn according to tumor volume and implantation timepoint (Fig. 2f). Knockout of METTL3 remarkably reduced tumor volume and weight. However, tumors arising from METTL3-depleted T24 cells containing dCas9-M3 and CDCP1-sgRNA2-PAMmer2 had significantly higher volume and weight than the non-targeting groups (Fig. 2e and f). These in vitro and in vivo results indicate that the RCas9-M3 system promotes BC progression.

Conclusions

Our constructed RCas9-M3 system can achieve targeted modification of mRNA and promote BC development. Thus, the RCas9-M3 system via lentiviral transduction is a powerful tool for exploring the biological effect of locus-specific m6A RNA methylation and presents a novel strategy for targeted interventions in BC or RNA modification defect-related diseases.

Supplementary Information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12943-020-01289-0.

Additional file 1: Supplementary Figure 1. MeRIP and RT-qPCR of epidermal growth factor receptor (EGFR) targeted by RCas9-M3 editors. (a) Western blot analysis of EGFR expression in control and METTL3-depleted cells (HeLa-KO-M3). (b) m6A enrichment of the EGFR mRNA 3’UTR in METTL3-depleted cells (HeLa-KO-M3) with the RCas9 system. All qRT-PCR data are presented as the mean ± SEM (n = 3). p < 0.05 and ****p < 0.0001. Supplementary Figure 2. The RCas9-M3 system binds to targeted mRNA. (a, b) RIP assays of EGFP after transfection of the EGFP mRNA-targeting RCas9-M3 system into METTL3-depleted HeLa cells compared to non-targeting sgRNA and PAMmer or EGFP alone. (a) Western blots of EGFP proteins. (b) qRT-PCR analysis of RCas9-M3 RIP in METTL3-depleted HeLa cells with EGFP 3’UTR primers. Data are presented as the mean ± SEM (n = 3). p < 0.05, ****p < 0.0001. Supplementary Figure 3. Effects of off-target methylation of RCas9-M3 and RCas9-M3 on cellular transcriptome abundances. (a) Sequence alignment between CDCP1-sgRNAs targeting sequences and SPECC1L, AP4S1, OR4A5, SL22A9, ST18 or ROR1 mRNAs. (b) SV-HUC-1 Cells were stably transfected with dCas9-METTL3 and λ2-sgRNA or CDCP1-sgRNA155–173/212, with m6A levels of SPECC1L, AP4S1, OR4A5, SL22A9, ST18 or ROR1 measured by m6A-RIP-qPCR analysis. (c, d) Volcano plots depicting differential gene transcript abundance in SV-HUC-1 cells transfected with (c) CDCP1-sgRNA155–173.
Abbreviations
BC: Bladder cancer; m6A: N6-methyladenosine; METTL3: Methyltransferase like 3; MeRIP: Methylated RNA immunoprecipitation; RT-qPCR: Real-time quantitative polymerase chain reaction; CDCP1: CUB domain-containing protein 1; EGFR: Epidermal growth factor receptor; EGGF: Enhanced green fluorescent protein; PAMmer: Protospacer adjacent motif; NLS: Nuclear localization signal

Acknowledgments
We would like to thank Editage (www.editage.cn) for English language editing.

Authors’ contributions
XY, QZ, and BL designed and performed the experiments; XJ, YH, and XZ performed some of the animal experiments; WJ conceived the project, wrote the manuscript, and critically revised the manuscript; DQ, GY, and JL provided key reagents. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (No. 81772699, No. 82073047, and No. 81472999), the Guangzhou People’s Livelihood Science and Technology Project (201803010052), the Key Natural Science Foundation of Guangdong (No. 8151012003000011), Key projects of Guangzhou Scientific Research (201804020023), and the National Key Research and Development Program of China (2016YFC1300800).

Availability of data and materials
All data generated or analyzed during this study are included in this manuscript (and its supplementary information files).

Ethics approval and consent to participate
All animal experimental procedures were approved by the Institutional Ethics Committee for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen university.

Consent for publication
All authors have agreed to publish this manuscript.

Competing interests
The authors declare no competing interests.

Author details
1Center for Translational Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. 2Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China. 3Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Guangzhou 510230, China. 4Department of Geratology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

Received: 5 October 2020 Accepted: 24 November 2020 Published online: 03 December 2020

References
1. Roundtree IA, He C. RNA epigenetics—chemical messages for posttranscriptional gene regulation. Curr Opin Chem Biol. 2016;30:46–51.
2. Boccaletto P, Machnicka MA, Pura E, Piatkowski P, Baginski B, Wierckzi TK, de Crécy-Lagard V, Ross R, Limbach PA, Kotter A, et al. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2018;46: D363–D367.
3. Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 2017;18:313–42.
4. Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M, Liang Y, Zhu F, Zhang Y, Zhang X, et al. The m6a methyltransferase METTL3 promotes bladder cancer progression via AFT4/NF-kB/MYC signaling network. Oncogene. 2019;38:3667–80.
5. Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, Yuan WB, Lu JC, Zhou ZZ, Lu Q, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18:1110.
6. Jin H, Ying X, Que B, Wang X, Chao Y, Zhang H, Yuan Z, Qi D, Lin S, Min W, et al. N6-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer. EBioMedicine. 2019;47: 195–207.
7. Yang F, Jin H, Que B, Chao Y, Zhang H, Ying X, Zhou Z, Yuan Z, Su J, Wu B, et al. Dynamic m6a mRNA methylation reveals the role of METTL3-m6A–CDCP1 signaling axis in cis axis carcinogenesis. Oncogene. 2019;38: 755–72.
8. Gu C, Wang Z, Zhou N, Li G, Kou Y, Luo Y, Wang Y, Yang J, Tian F. Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6a-methyladenosine of Notch1. Mol Cancer. 2019;18:168.
9. Nelles DA, Fang MY, O’Connell MR, Xu JL, Markmiller SJ, Doubna JA, Yeo GW. Programmable RNA tracking in live cells with CRISPR/Cas9. Cell. 2016;165: 488–96.
10. Lin S, Cho J, Du P, Triboulet R, Gregory R. The m6a methyltransferase mettl3 promotes translation in human cancer cells. Mol Cell. 2016;62: 335–45.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.